Lymphoproliferative Disorder Treatment Market size is estimated to reach USD 11 billion by the end of 2035, growing at a CAGR of 7% during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of lymphoproliferative disorder treatment was over USD 5 billion. The growth of the market can be attributed to the increasing number of lymphoproliferative disorders such as leukemia and lymphoma throughout the world. For instance, in 2020, the frequency of leukemia mortality in Spain was estimated to be around 4365 individuals. Further, the growing awareness in people regarding lymphoproliferative disorders, along with the surge in Sezary syndrome, T-cell prolymphocytic leukemia, adult T-cell leukemia-lymphoma, and big granulated lymphocyte leukemia is also estimated to skyrocket the growth of the market as these all conditions are related with the T-cell chronic lymphoproliferative disorders.
In addition to these, factors that are believed to fuel the market growth of lymphoproliferative disorders include the rise in organ transplantation cases throughout the world. Since the process of organ transplantation is raising the risk of post-transplant lymphoproliferative disorder (PTLD). For instance, more than 150,409 organ transplants took place globally in 2021. Additionally, the growing demand for effective treatments and therapies, coupled with the substantial expansion in research and development activities are also projected to drive the market growth further during the projected time frame.
Growth Drivers
Worldwide Expanding Prevalence of Lymphoma Cases – Lymphoma is a lymphatic malignancy that damages the immune system. It starts in the immune system's infection-fighting cells called lymphocytes. These cells can be found in the lymph nodes, spleen, thymus, bone marrow, and other organs. Lymphocytes alter and develop uncontrollably in lymphoma patients. There are two types of lymphoma including Hodgkin’s and non-Hodgkin lymphoma. Several types of lymphocyte cells are involved in non-Hodgkin (NHL) and Hodgkin lymphoma. Every variation of lymphoma develops at varying rates and responds to treatment accordingly. Therefore, the rising prevalence of lymphoma across the globe is estimated to drive the market growth of lymphoproliferative disorder treatment in the coming years. For instance, worldwide around 544,452 cases of non-Hodgkin lymphoma (NHL) were diagnosed in 2020, and an expected nearly 879,000 additional NHL cases are expected to be diagnosed throughout the world by 2040.
Rise in the Cases of Chronic lymphocytic leukemia (CLL) - Chronic lymphocytic leukemia (CLL) is a kind of blood and bone marrow cancer. Chronic lymphocytic leukemia's exact cause is still unknown. There are several genetic mutations in the DNA of blood-producing cells. These mutations lead blood cells to produce aberrant lymphocytes that are ineffective against infection. Thus, the significant upsurge in chronic lymphocytic leukemia (CLL) is also anticipated to fuel the market growth over the forecast period. For instance, in 2023, the United States is expected to have around 19,850 new cases and nearly 5,690 mortalities from chronic lymphocytic leukemia (CLL).
Globally Increasing Healthcare Expenditure – According to World Bank figures, worldwide healthcare expenditure surged by 9.83% in 2019. It is predicted that this expansion would continue over the forecast period.
An Upsurge in Novel Targeted Treatments - With frontline targeted treatment, patients with non-Hodgkin lymphoma (NHL) can achieve significant response and survival rates. Thus, several kinds of novel treatments including targeted treatment have been discovered to effectively treat NHL. For instance, Kinase inhibitor therapy, a kind of targeted therapy, prevents cancer cells from proliferating by blocking specific proteins. Copanlisib, idelalisib, duvelisib, and umbralisib are kinase inhibitor medications that block P13K proteins and may help keep lymphoma cells from spreading. They are used to treat follicular NHLs that have not improved or relapsed after at least two prior treatments. Umbralisib is also used to treat patients with marginal zone lymphoma who have relapsed or are not responding to treatment.
Rising Research and Development Investments – For instance, global R&D investments in the pharmaceutical sector exceeded around USD 256 billion in 2021.
Challenges
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~7% |
|
Base Year Market Size (2022) |
~ USD 5 Billion |
|
Forecast Year Market Size (2035) |
~ USD 11 Billion |
|
Regional Scope |
|
Drug Class (Immunomodulatory Agents, Steroids, Cytotoxic Agents)
The global lymphoproliferative disorder treatment market is segmented and analyzed for demand and supply by drug class into immunomodulatory agents, steroids, cytotoxic agents, and others. Out of these four types of segments, the immunomodulatory agent segment is estimated to gain the largest market share of about ~58% in the year 2035. The growth of the segment can be attributed to the effectiveness of immuno-modulator drugs to efficiently improve the performance of an individual’s immune system. Moreover, an increase in the use of novel receptors, and their effectiveness in immunotherapy is also estimated to fuel the market growth in the coming years. For instance, Antigen Receptor Chimeric (CAR) T immunotherapy is a type of novel immunotherapy that modifies the patient's immune system T cells so that they can attack specific proteins on the surface of cancer cells. In addition to this, Brentuximab vedotin (Adcetris) is a chemotherapeutic medication that also contains an anti-CD30 antibody (an antibody-drug conjugate). When the chemo medication is brought to lymphoma cells by the antibody, it enters the cells and destroys them. It may be administered as the first treatment coupled with chemotherapy or if the lymphoma has resurfaced following prior treatments to treat specific kinds of T-cell lymphoma.
Distribution Channel (Online Pharmacies, Retail Pharmacies, Hospital Pharmacies)
The global lymphoproliferative disorder treatment market is also segmented and analyzed for demand and supply by distribution channel into online pharmacies, retail pharmacies, and hospital pharmacies. Amongst these three segments, the hospital pharmacies segment is expected to garner a significant share of around ~60% in the year 2035. The growth of the segment can be credited to the surging patient pool of lymphoproliferative disorders throughout the world, followed by the surge in the proportion of people coming to the hospitals for treatment and to collect the required medicines from the hospital pharmacies. People also choose hospital pharmacies over making an online purchase as it is more convenient, and all the prescribed drugs are available at a one-stop shop. On the other hand, the online pharmacies segment is projected to witness a notable CAGR during the forecast period, on the back of the mounting awareness amongst people for these online platforms throughout the world. Moreover, purchasing medicines via these online platforms help the user to receive the prescribed drugs directly at their homes, without the need to visit offline stores. In addition to this, several online pharmaceutical businesses are also offering wide discounts to lure their customers as part of their customer retention policy. This, as a result, is anticipated to create numerous opportunities for the growth of the segment in the coming years.
Our in-depth analysis of the global market includes the following segments:
|
By Route of Administration |
|
|
By Drug Class |
|
|
By Application |
|
|
By Distribution Channel |
|
North American Market Forecast
The North American lymphoproliferative disorder treatment market, amongst the market in all the other regions, is projected to hold the largest market share of about ~45% by the end of 2035. The growth of the market can be attributed majorly to the increasing frequency of the lymphoproliferative disorder in the region along with an increase in focus on research and development for the effective treatment of such disorders. For instance, around 178,520 people in the US were estimated to be diagnosed with leukemia, lymphoma, or myeloma in 2020. In addition, the increasing awareness among people about lymphoproliferative disorders, followed by the rising development and launch of novel therapeutics as well as expanding incorporation of genomics in cancer care and treatment is also estimated to drive the market growth further during the forecast period in the region.
Europe Market Forecast
The European lymphoproliferative disorder treatment market, amongst the market in all the other regions, is projected to hold the second largest share of about ~21% during the forecast period. The growth of the market can be attributed majorly to the increasing demand for effective therapies to treat lymphoproliferative disorders, followed by the surging proportion of lymphoma, and leukemia cases in the countries such as Germany, Italy, and so on in the region. For instance, in Italy, over 90 thousand people had a leukemia diagnosis in the year 2022. With around 46,900 cases, the majority were men. Moreover, the increasing advancement in medical technology, and rising implementation of genetic engineering, and nanotechnology for the diagnosis of lymphoproliferative disorders are also anticipated to propel the growth of the market in the region during the projected time frame.
APAC Market Statistics
Further, the market in the Asia Pacific, amongst the market in all the other regions, is projected to hold a majority of the share of about ~16% by the end of 2035. The growth of the market can be attributed majorly to the increasing awareness amongst the people regarding these disorders, along with the significant increase in the lymphoma patient pool is also anticipated to spur the market growth in the region. In addition to this, the fast approval of novel drugs in nations such as Japan, and China is also estimated to accelerate the market growth in the APAC region during the forecast period.
ADC Therapeutics SA disclosed its Phase 2 clinical trial findings for camidanlumab tesirine (Cami) in relapsed or refractory (r/r) Hodgkin lymphoma. Cami has been examined in a key Phase 2 clinical trial in individuals who have relapsed or refractory Hodgkin lymphoma, as well as a Phase 1b clinical trial in tumor cells as monotherapy and in combination with pembrolizumab.
Genentech, Inc. has announced that the FDA has granted approval for Lunsumio (mosunetuzumab-axgb) for the treatment of adult individuals who have relapsed or refractory (R/R) follicular lymphoma (FL) following two or more lines of systemic therapy. This indication has been granted rapid approval based on the response rate.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?